The immunoglobulin superfamily member 3 (IGSF3) promotes hepatocellular carcinoma progression through activation of the NF-κB pathway. 2020

Ping Sheng, and Huirong Zhu, and Wenxiu Zhang, and Yanan Xu, and Wenxue Peng, and Jing Sun, and Mingqi Gu, and Hongchi Jiang
Department of General Surgery, Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin 150081, China.

BACKGROUND Patients with hepatocellular carcinoma (HCC) suffer from a high fatality rate, likely due to increased incidence of tumor relapse and metastasis. Understanding the molecular mechanisms that contribute to HCC development and progression is vital for the discovery of new treatment targets. This study aims to explore the expression profiles and functions of immunoglobulin superfamily member 3 (IGSF3) in HCC. METHODS We evaluated IGSF3 levels in HCC and normal tissues using bioinformatics, western blot, quantitative real-time PCR (qRT-PCR), and immunohistochemistry. We also conducted proliferation assays, colony formation assays, flow cytometry, cell migration assay, cell invasion assay, qRT-PCR, and western blotting in HCC cell lines. Immunofluorescence and western blotting further used to study the IGSF3 pathway. A mouse xenograft model was utilized to examine the influence of IGSF3 on HCC growth in vivo. RESULTS IGSF3 levels were higher in HCC tissues and cell lines. Silencing of IGSF3 via lentiviral vector system (LV) inhibited migration, invasion, and growth of HCC cell lines in vitro as well as tumor growth in vivo. Overexpression of IGSF3 promoted result in vitro. Importantly, we found that IGSF3 activates the NF-κB pathway to promote tumorigenic features in HCC cell lines. CONCLUSIONS We found that IGSF3 can be used as a novel biomarker for HCC detection. Moreover, IGSF3 elicits HCC progression by activating the NF-κB pathway. As such, our data provides potential options for therapeutic targets in patients with HCC.

UI MeSH Term Description Entries

Related Publications

Ping Sheng, and Huirong Zhu, and Wenxiu Zhang, and Yanan Xu, and Wenxue Peng, and Jing Sun, and Mingqi Gu, and Hongchi Jiang
January 2023, Annals of hepatology,
Ping Sheng, and Huirong Zhu, and Wenxiu Zhang, and Yanan Xu, and Wenxue Peng, and Jing Sun, and Mingqi Gu, and Hongchi Jiang
July 2020, Cell death & disease,
Ping Sheng, and Huirong Zhu, and Wenxiu Zhang, and Yanan Xu, and Wenxue Peng, and Jing Sun, and Mingqi Gu, and Hongchi Jiang
May 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,
Ping Sheng, and Huirong Zhu, and Wenxiu Zhang, and Yanan Xu, and Wenxue Peng, and Jing Sun, and Mingqi Gu, and Hongchi Jiang
November 2020, Life sciences,
Ping Sheng, and Huirong Zhu, and Wenxiu Zhang, and Yanan Xu, and Wenxue Peng, and Jing Sun, and Mingqi Gu, and Hongchi Jiang
September 2020, BMC cancer,
Ping Sheng, and Huirong Zhu, and Wenxiu Zhang, and Yanan Xu, and Wenxue Peng, and Jing Sun, and Mingqi Gu, and Hongchi Jiang
May 2019, Clinical laboratory,
Ping Sheng, and Huirong Zhu, and Wenxiu Zhang, and Yanan Xu, and Wenxue Peng, and Jing Sun, and Mingqi Gu, and Hongchi Jiang
March 2024, Cell biochemistry and function,
Ping Sheng, and Huirong Zhu, and Wenxiu Zhang, and Yanan Xu, and Wenxue Peng, and Jing Sun, and Mingqi Gu, and Hongchi Jiang
November 2015, British journal of cancer,
Ping Sheng, and Huirong Zhu, and Wenxiu Zhang, and Yanan Xu, and Wenxue Peng, and Jing Sun, and Mingqi Gu, and Hongchi Jiang
April 2024, Discovery medicine,
Ping Sheng, and Huirong Zhu, and Wenxiu Zhang, and Yanan Xu, and Wenxue Peng, and Jing Sun, and Mingqi Gu, and Hongchi Jiang
November 2022, Biology direct,
Copied contents to your clipboard!